Analysts Set Chemed Corporation (NYSE:CHE) PT at $501.50

Chemed Corporation (NYSE:CHE) has been given an average recommendation of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $480.25.

A number of analysts have weighed in on CHE shares. Royal Bank Of Canada increased their target price on Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a research note on Monday, April 27th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Weiss Ratings upgraded shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Finally, Bank of America boosted their price objective on shares of Chemed from $450.00 to $510.00 and gave the company a “neutral” rating in a research report on Thursday.

Insider Buying and Selling

In other Chemed news, Director Andrea R. Lindell sold 1,347 shares of Chemed stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the sale, the director directly owned 4,578 shares of the company’s stock, valued at $2,047,876.74. The trade was a 22.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the sale, the chief executive officer owned 90,219 shares of the company’s stock, valued at $37,993,927.47. The trade was a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Chemed

A number of large investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. raised its position in shares of Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after acquiring an additional 76 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Chemed by 67.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock worth $5,534,000 after acquiring an additional 4,560 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Chemed during the second quarter valued at about $579,000. Brown Advisory Inc. raised its position in shares of Chemed by 36.9% in the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock valued at $267,000 after purchasing an additional 148 shares during the last quarter. Finally, Cerity Partners LLC boosted its stake in Chemed by 237.7% in the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock worth $2,165,000 after purchasing an additional 3,133 shares in the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed Trading Up 2.2%

CHE opened at $490.11 on Friday. The stock has a market cap of $6.50 billion, a price-to-earnings ratio of 26.71, a P/E/G ratio of 1.77 and a beta of 0.52. The stock’s 50 day moving average price is $441.89 and its 200-day moving average price is $428.28. Chemed has a one year low of $365.20 and a one year high of $492.30. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.83 and a current ratio of 0.85.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.30 by $0.35. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The firm had revenue of $657.51 million during the quarter, compared to analyst estimates of $659.22 million. During the same period last year, the company earned $5.63 EPS. Chemed’s quarterly revenue was up 1.6% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. On average, equities analysts forecast that Chemed will post 22.67 EPS for the current year.

Chemed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Thursday, May 28th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Thursday, May 28th. Chemed’s payout ratio is currently 13.08%.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.